Lipid–protamine–DNA-mediated antigen delivery to antigen-presenting cells results in enhanced anti-tumor immune responses
Open Access
- 1 May 2003
- journal article
- research article
- Published by Elsevier in Molecular Therapy
- Vol. 7 (5) , 640-648
- https://doi.org/10.1016/s1525-0016(03)00064-9
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- CD8α2 CD11b+ Dendritic Cells Present Exogenous Virus-like Particles to CD8+ T Cells and Subsequently Express CD8α and CD205 MoleculesThe Journal of Experimental Medicine, 2002
- Enhancement of antitumor immunity by prolonging antigen presentation on dendritic cellsNature Biotechnology, 2002
- Biological activities and molecular targets of the human papillomavirus E7 oncoproteinOncogene, 2001
- Stabilized plasmid-lipid particles for systemic gene therapyGene Therapy, 2000
- Characterization of cationic lipid-protamine–DNA (LPD) complexes for intravenous gene deliveryGene Therapy, 1998
- Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cellsEuropean Journal of Immunology, 1993
- T cell immunity after a viral infection versus T cell tolerance induced by soluble viral peptidesEuropean Journal of Immunology, 1993
- The differential expression of homing and adhesion molecules on virgin and memory T cells in the mouseCellular Immunology, 1991
- Naive and memory T cells show distinct pathways of lymphocyte recirculation.The Journal of Experimental Medicine, 1990
- Class 1 (unique) tumor antigens of human melanoma. Identification of a 90,000 dalton cell surface glycoprotein by autologous antibody.The Journal of Experimental Medicine, 1984